Developing new hope for patients and families

Pulmonary Arterial Hypertension (PAH) is a degenerative and life-threatening disease that makes it difficult for the heart to pump blood to the lungs to be oxygenated and may ultimately lead to heart failure. Current PAH treatment options only address the symptoms, slowing but not preventing disease progression. New therapies that address the underlying cause of disease are urgently needed.

In January 2017, VIVUS acquired exclusive, worldwide rights to develop and commercialize tacrolimus and ascomycin for the treatment of PAH and related vascular diseases.

Pulmonary arterial hypertension is a degenerative disease with current treatment options that only address the symptoms to slow the progression of the disease. We are excited about the potential of developing treatment options to significantly improve the quality of life and life expectancy of PAH patients.

Links and Information

BACK TO TOP